Vera Therapeutics Inc (VERA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.03B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vera Therapeutics Inc (VERA) Earnings: Report Dates and Results
Vera Therapeutics (VERA) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Vera Therapeutics reported EPS of -$1.30, above the -$1.72 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VERA has an expected report date of Feb 24, 2027.
VERA Earnings Call
The latest VERA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 23 quarters below that had an estimate, VERA beat 8 and missed 15. The widest gap in the table came in the quarter ended Mar 31, 2021, when EPS landed 530.41% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.30 | -$1.72 | -$1.80 - -$1.39 | +24.42% | Beat | N/A | 8 | 1 up, 0 down | Nov 5, 2026 |
| Jun 30, 2026 | -$1.52 | -$1.60 | -$1.73 - -$1.38 | +5.00% | Beat | N/A | 7 | 1 up, 0 down | Aug 10, 2026 |
| Mar 31, 2026 | -$1.69 | -$1.37 | -$1.66 - -$1.20 | -23.36% | Miss | N/A | 5 | 1 up, 3 down | May 7, 2026 |
| Dec 31, 2025 | -$1.39 | -$1.34 | -$1.62 - -$1.11 | -3.73% | Miss | N/A | 8 | 2 up, 0 down | Feb 26, 2026 |
| Sep 30, 2025 | -$1.26 | -$1.20 | -$1.30 - -$0.93 | -5.00% | Miss | N/A | 7 | 0 up, 0 down | Nov 5, 2025 |
| Jun 30, 2025 | -$1.20 | -$0.62 | -$0.90 - $0.69 | -93.55% | Miss | N/A | 7 | N/A | Aug 5, 2025 |
| Mar 31, 2025 | -$0.81 | -$0.78 | -$0.81 - -$0.76 | -3.85% | Miss | N/A | 4 | 1 up, 0 down | May 6, 2025 |
| Dec 31, 2024 | -$0.72 | -$0.81 | -$0.90 - -$0.62 | +11.11% | Beat | N/A | 3 | 2 up, 1 down | Feb 26, 2025 |
| Sep 30, 2024 | -$0.85 | -$0.62 | -$0.81 - -$0.58 | -37.10% | Miss | N/A | 9 | 1 up, 0 down | Nov 7, 2024 |
| Jun 30, 2024 | -$0.62 | -$0.54 | -$0.65 - -$0.48 | -14.81% | Miss | N/A | 8 | 0 up, 0 down | Aug 8, 2024 |
| Mar 31, 2024 | -$0.56 | -$0.53 | -$0.60 - -$0.46 | -5.66% | Miss | N/A | 6 | 0 up, 0 down | May 9, 2024 |
| Dec 31, 2023 | -$0.58 | -$0.51 | -$0.58 - -$0.42 | -13.73% | Miss | N/A | 9 | 0 up, 0 down | Mar 20, 2024 |
| Sep 30, 2023 | -$0.45 | -$0.54 | -$0.70 - -$0.50 | +16.67% | Beat | N/A | 6 | 1 up, 0 down | Nov 9, 2023 |
| Jun 30, 2023 | -$0.46 | -$0.74 | -$0.82 - -$0.42 | +37.84% | Beat | N/A | 6 | 0 up, 0 down | Aug 10, 2023 |
| Mar 31, 2023 | -$0.80 | -$0.45 | -$0.80 - -$0.45 | -77.78% | Miss | N/A | 6 | 0 up, 2 down | May 11, 2023 |
| Dec 31, 2022 | -$1.18 | -$0.90 | -$1.02 - -$0.68 | -31.11% | Miss | N/A | 6 | 0 up, 0 down | Mar 28, 2023 |
| Sep 30, 2022 | -$0.91 | -$0.90 | -$0.90 - -$0.64 | -1.11% | Miss | N/A | 6 | 0 up, 0 down | Nov 9, 2022 |
| Jun 30, 2022 | -$0.55 | -$0.78 | N/A | +29.49% | Beat | N/A | N/A | 0 up, 0 down | Aug 10, 2022 |
| Mar 31, 2022 | -$0.71 | -$0.64 | -$0.73 - -$0.62 | -10.94% | Miss | N/A | 5 | 0 up, 0 down | May 16, 2022 |
| Dec 31, 2021 | -$0.79 | -$0.46 | -$0.49 - -$0.44 | -71.74% | Miss | N/A | 2 | 0 up, 0 down | Mar 24, 2022 |
| Sep 30, 2021 | -$0.36 | -$0.59 | -$0.75 - -$0.44 | +38.98% | Beat | N/A | 2 | 1 up, 0 down | Nov 10, 2021 |
| Jun 30, 2021 | -$0.33 | -$0.45 | -$0.45 - -$0.33 | +26.67% | Beat | N/A | 2 | N/A | Aug 16, 2021 |
| Mar 31, 2021 | -$12.23 | -$1.94 | N/A | -530.41% | Miss | N/A | N/A | N/A | Apr 23, 2021 |
| Dec 31, 2020 | -$2.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2020 |
| Sep 30, 2020 | -$0.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2020 |
| Jun 30, 2020 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2020 |
| Mar 31, 2020 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$4.66, after -$2.75 the year before. It was -$2.51 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$4.66 | N/A |
| Dec 31, 2024 | -$2.75 | N/A |
| Dec 31, 2023 | -$2.29 | N/A |
| Dec 31, 2022 | -$3.35 | N/A |
| Dec 31, 2021 | -$13.71 | N/A |
| Dec 31, 2020 | -$2.51 | N/A |
Earnings Calls
The only earnings call listed below, 2026Q3 for the period ended Sep 30, 2026, runs about 4,700 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,687 | 16 |
2026Q3 Earnings Call
Opening remarks
Joshua Qin Vice President of Corporate Finance and Investor Relations Thank you, operator, and thank you, everyone, for joining us. Earlier today, we issued a press release announcing our business highlights and financial results for the quarter ended September 30, 2026. A copy of the press release is available in the Investors and Media section of our website at ir.veratx.com. Before we begin, I would like to remind everyone that we will be making various remarks about future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The company cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. We encourage everyone to review the company's filings with the SEC, including, without limitation, the company's most recent Form 10-K and Form 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. In addition, today's discussion includes results from ongoing clinical trials of atacicept in investigational uses that have not been approved by the FDA or any other regulatory authority. The full prescribing information for TRUTAKNA, including important safety information, is available on our website. Furthermore, the content of this webcast contains time-sensitive information that is accurate only as of the date of the live broadcast, November 5, 2026. Vera undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this broadcast. This webcast is being recorded, and an archive will be available on our website for 30 days. With that, I will turn the call over to Dr. Marshall Fordyce, Founder and Chief Executive Officer. Marshall?
Marshall Fordyce Founder and Chief Executive Officer Thank you, Josh, and welcome, everyone. Joining me today are Dr. Robert Brenner, our Chief Medical Officer; Matt Skelton, our Chief Commercial Officer; and Sean Grant, our Chief Financial Officer. The third quarter marked a major turning point for Vera. Following accelerated approval from the FDA in July, we launched TRUTAKNA, the first therapy approved in the U.S. that targets both BAFF and APRIL to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Since the accelerated approval of TRUTAKNA on July 7, we have received approximately 700 patient start forms to date. This early momentum exemplifies our longstanding confidence in TRUTAKNA's potential to become a foundational therapy for IgA nephropathy, and it represents an important first step in delivering on our commitment to people living with this disease. We're sharing this figure today because we believe it's the best measure of demand at this early stage of launch.
Frequently Asked Questions About VERA
When is Vera Therapeutics's next earnings date?
Vera Therapeutics's next earnings report is expected for Feb 24, 2027.
Did VERA beat earnings estimates last quarter?
Yes. Vera Therapeutics reported EPS of -$1.30 for the quarter ended Sep 30, 2026, above the -$1.72 estimate, a 24.42% surprise.
What EPS do analysts expect from VERA next quarter?
The consensus EPS estimate for Vera Therapeutics for the quarter ending Dec 31, 2026 is -$1.40 from 13 analysts, with estimates from -$2.12 to -$1.17.
How often does VERA beat earnings estimates?
Vera Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -11.12%.
VERA pages: Overview, Earnings, Forecast, Financials, Competitors